Collaborative Arrangements and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2018

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2018, 2017 and 2016, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Years Ended December 31,
	2018			2017			2016
				(as revised)
SPINRAZA royalties (commercial revenue)	$	237.9		$	112.5		$	0.9
R&D revenue		137.1			150.6			248.8
Total revenue from our relationship with Biogen		375.0			263.1			249.7
Percentage of total revenue		63	%		51	%		67	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2018, 2017 and 2016, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Years Ended December 31,
	2018			2017			2016
				(as revised)
R&D revenue	$	120.7		$	21.6		$	41.3
Percentage of total revenue		20	%		4	%		11	%

Bayer [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2018, 2017 and 2016, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):

	Years Ended December 31,
	2018			2017			2016
				(as revised)
R&D revenue	$	5.0		$	67.1		$	5.4
Percentage of total revenue		1	%		13	%		1	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2018, 2017 and 2016, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):

	Years Ended December 31,
	2018			2017			2016
				(as revised)
R&D revenue	$	1.6		$	14.8		$	17.5
Percentage of total revenue		0	%		3	%		5	%

Janssen Biotech, Inc. [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2018, 2017 and 2016, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):

	Years Ended December 31,
	2018			2017			2016
				(as revised)
R&D revenue	$	6.6		$	36.0		$	24.8
Percentage of total revenue		1	%		7	%		7	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2018, 2017 and 2016, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Years Ended December 31,
	2018			2017			2016
				(as revised)
R&D revenue	$	8.3		$	55.7		$	10.7
Percentage of total revenue		1	%		11	%		3	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2018 and 2017, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):

	Years Ended December 31,
	2018			2017
				(as revised)
R&D revenue	$	50.6		$	43.4
Percentage of total revenue		8	%		8	%